Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 95
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 11 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Tirzepatide improves MASH resolution and fibrosis in diabetes patients
Last updated July 17, 2026
Key finding
Greater body weight reductions were observed in responders for MASH resolution (−16.0% vs. −7.0%; P < 0.001).
This study analyzed the effects of tirzepatide on metabolic dysfunction-associated steatohepatitis (MASH) in participants from the SYNERGY-NASH trial, revealing significant improvements in body weight and HbA1c levels.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study analyzed the effects of tirzepatide on metabolic dysfunction-associated steatohepatitis (MASH) in participants from the SYNERGY-NASH trial, revealing significant improvements in body weight and HbA1c levels.
Clinical relevance
These findings are significant as they suggest that tirzepatide may provide a new therapeutic option for patients with MASH, potentially improving their metabolic health and reducing the risk of liver-related complications.
Keep in mind
The study's post hoc analysis may limit the strength of conclusions. Sample size and demographic diversity were not specified. Long-term effects of tirzepatide on MASH were not assessed.
Published in
Journal Reference
Publication details and source links for this paper.
Cyrielle C, Kenneth C, Julio R, et al. Tirzepatide for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis: A Post Hoc Analysis of the SYNERGY-NASH Trial. Diabetes Care. 2025;48(12):2074-2083. doi:10.2337/dc25-1306
Main Effects
Tirzepatide resulted in a 16% reduction in body weight for MASH responders (P < 0.001).
HbA1c levels decreased by 1.2% in MASH responders receiving tirzepatide (P < 0.001).
No significant differences were found in HbA1c achievement among fibrosis responders and nonresponders in the placebo group.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Tirzepatide and Body weight, Fibrosis improvement percentage, Improvement in liver fat in MASH responders, and 2 more.
This study contributes evidence to
Primary intervention
Tirzepatide
Primary outcomes
- Body weight
- Fibrosis improvement percentage
- Improvement in liver fat in MASH responders
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
2
Related topics
5
Evidence pairs
236
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
GLP-1 Receptor Agonists and Body Weight
Related evidence
Evidence topic
Weight Loss
Save evidence
Evidence topic
GLP-1 Receptor Agonists
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Fibrosis improvement percentage
Tirzepatide → Fibrosis improvement percentage
Tirzepatide → Fibrosis improvement percentage
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerImprovement in liver fat in MASH responders
Tirzepatide → Improvement in liver fat in MASH responders
Tirzepatide → Improvement in liver fat in MASH responders
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerReduction in HbA1c levels in MASH responders
Tirzepatide → Reduction in HbA1c levels in MASH responders
Tirzepatide → Reduction in HbA1c levels in MASH responders
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResolution of metabolic dysfunction associated steatohepatitis
Tirzepatide → Resolution of metabolic dysfunction associated steatohepatitis
Tirzepatide → Resolution of metabolic dysfunction associated steatohepatitis
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Tirzepatide led to a significant 16% weight reduction in MASH responders.
- MASH responders on tirzepatide experienced a 1.2% decrease in HbA1c levels.
- No significant differences in HbA1c achievement were observed in placebo nonresponders.
Who this applies to
- Adults diagnosed with metabolic dysfunction-associated steatohepatitis.
- Individuals with obesity and type 2 diabetes.
Keep in Mind
- Results are based on a post hoc analysis, which may introduce bias.
- The study's findings may not be generalizable to all populations.
- Further research is needed to confirm long-term efficacy and safety.
Between the Lines
- The study's post hoc analysis may limit the strength of conclusions.
- Sample size and demographic diversity were not specified.
- Long-term effects of tirzepatide on MASH were not assessed.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Body Weight, GLP-1 Receptor Agonists and Fibrosis improvement percentage.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 95
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 11 studies
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Body Weight Evidence Hub
All studies measuring Body Weight
11 studies
outcome_hubMeasures Body Weight as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
11 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Fibrosis improvement percentage Evidence Hub
All studies measuring Fibrosis improvement percentage
1 studies
outcome_hubMeasures Fibrosis improvement percentage as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Tirzepatide and Body weight
Intervention: TirzepatideOutcome: Body weight
11 results
All studies on Tirzepatide and Fibrosis improvement percentage
Intervention: TirzepatideOutcome: Fibrosis improvement percentage
1 results
All studies on Tirzepatide
Intervention: Tirzepatide
11 results
All studies measuring Body weight
Outcome: Body weight
11 results
All studies measuring Fibrosis improvement percentage
Outcome: Fibrosis improvement percentage
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists appears to improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 83.3 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 30 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Tirzepatide improve fibrosis improvement percentage?
Emerging Evidence
Tirzepatide appears to improve Fibrosis improvement percentage.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Fibrosis improvement percentage
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Tirzepatide improve improvement in liver fat in mash responders?
Emerging Evidence
Tirzepatide appears to improve Improvement in liver fat in MASH responders.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Improvement in liver fat in MASH responders
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Tirzepatide improve reduction in hba1c levels in mash responders?
Emerging Evidence
Tirzepatide appears to improve Reduction in HbA1c levels in MASH responders.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Reduction in HbA1c levels in MASH responders
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Tirzepatide improves glycemic control in early-onset type 2 diabetesTirzepatide improves cardiometabolic health in obesity.Tirzepatide enhances insulin sensitivity in type 2 diabetesTirzepatide improves glycemic control and weight loss in type 2 diabetesTirzepatide improves quality of life in type 2 diabetes patients
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.